Proopiomelanocortin

Mechanism of Action

• In anterior pituitary: PC1 cleaves POMC to ACTH and beta-LPH; minimal alpha-MSH production
• In hypothalamus and skin: PC1+PC2 cleave ACTH to alpha-MSH (MC1R/MC4R agonist) + CLIP; beta-LPH to beta-endorphin
• ACTH binds MC2R on adrenal cortex, driving cortisol synthesis and secretion; central stress-axis effector
• Alpha-MSH via MC4R in hypothalamus is the primary satiety signal, directly opposing AgRP-mediated hunger drive
• Beta-endorphin is the most potent endogenous mu-opioid peptide: pain modulation, euphoria, and stress analgesia

Research Findings

• Loss-of-function POMC mutations cause severe early-onset obesity, adrenal insufficiency, and red hair (MC1R/MC4R/MC2R pathways all affected)
• Setmelanotide (MC4R agonist) approved for POMC-deficiency obesity in 2020, the first POMC-pathway targeted drug
• POMC neurons in arcuate nucleus are critical nodes in leptin-regulated energy homeostasis; leptin directly stimulates POMC transcription
• POMC-derived ACTH overproduction causes Cushing disease; MSH overproduction in ectopic ACTH causes hyperpigmentation
• Skin POMC/alpha-MSH production increases with UV exposure, linking tanning response to central melanocortin system

Research Protocols

• No direct POMC administration protocols; active fragments administered individually (see ACTH, alpha-MSH, beta-endorphin entries)
• POMC genetic testing: clinical workup for severe early-onset obesity and adrenal insufficiency
• Setmelanotide (Imcivree): 2-3 mg SC daily for POMC-deficiency obesity (approved therapeutic)
• Research: POMC-Cre mouse lines for selective ablation of POMC neurons to study energy balance

Interactions

• Leptin: master regulator of POMC transcription; leptin deficiency dramatically reduces POMC neuron activity
• AgRP/NPY: functional antagonists to POMC-derived alpha-MSH at MC4R; balance drives feeding behavior
• Glucocorticoids: negative feedback on CRH/ACTH via pituitary POMC suppression (hypothalamic-pituitary-adrenal axis)

Safety Profile

POMC deficiency causes life-threatening adrenal insufficiency and morbid obesity. POMC excess (Cushing) causes metabolic syndrome, hypertension, and immune suppression. Setmelanotide (MC4R agonist derived from POMC biology) causes hyperpigmentation and spontaneous erections at therapeutic doses.

Legal & Regulatory

POMC itself not therapeutic; setmelanotide (downstream pathway agonist) FDA-approved 2020 for genetic obesity